EUVIMEDEUVIMED entdecken
Crossref

Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study

Stefano Arcangeli, Chiara Chissotti, Federica Ferrario, Raffaella Lucchini, Maria Belmonte, Giorgio Purrello, Riccardo Ray Colciago, Elena De Ponti, Valeria Faccenda, Denis Panizza

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2024.06.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Stefano Arcangeli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; School of Medicine and Surgery, University of Milan Bicocca, M…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Quality of Life, Gastrointestinal Tract, Urethra. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess late gastrointestinal (GI) and genitourinary (GU) side effects in patients with organ-confined unfavorable prostate cancer (PCa) treated with single-dose ablative radiation therapy (SDRT). METHODS AND MATERIALS: Thirty patients enrolled in a single-arm prospective trial received 24 Gy SDRT to the whole prostate with urethra-sparing and organ motion control delivered on a Linac platform with a 10 MV flattening filter-free single partial arc. Androgen deprivation therapy was prescribed as per standard of care. Treatment-related acute and late GU and GI toxicities (Common Terminology Criteria for Adverse Events_v5 scale) and quality of life (QoL) outcomes (European Organisation for Research and Treatment of Cancer [EORTC] QLQ-PR25/C30, International Prostate Symptom Score [IPSS]) were assessed at different time points. Minimal important difference (MID) was established as a change of >0.5 pooled standard deviations from baseline. Statistical analysis included analysis of variance and logistic regression. RESULTS: Median follow-up was 18 months (range, 6-31 months), with no ≥G3 late side effects observed. G2 late GI and G2 late GU toxicities occurred in 1 and 2 patients, respectively. GI toxicity of any grade correlated with maximum rectal dose (P = .021). Lower baseline QoL score (P = .025), higher baseline IPSS score (P = .049), acute GU toxicity (P = .029), and acute urinary domain MID (P = .045) predicted GU toxicity of any grade. In multivariate analysis (MVA), only baseline QoL score (odds ratio [OR], 0.95, P = .031) and acute GU toxicity (OR, 8.4, P = .041) remained significant. Significant QoL change was observed only in the urinary domain (P = .005), with a median increase from 8 to 17. Late urinary MID correlated with acute urinary MID (P = .003), acute QoL MID (P = .029), acute GU toxicity (P = .030), and lower baseline urinary score (P = .033). In MVA, only acute urinary MID predicted late urinary MID (OR, 9.7, P = .035). CONCLUSIONS: Our findings provide promising data on the feasibility and safety of 24 Gy whole-gland SDRT with urethra-sparing and organ motion control, in association with androgen deprivation therapy and an adequate prophylactic medication, in organ-confined unfavorable PCa. Long-term follow-up is needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsQuality of LifeGastrointestinal TractUrethraHumansMaleProspective StudiesAgedMiddle AgedRadiation InjuriesAndrogen AntagonistsAged, 80 and overOrgan Sparing TreatmentsOrgan MotionRadiotherapy DosageUrogenital SystemRectumOrgans at Risk

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Radiation Oncology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.
  • School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.
  • School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; Medical Physics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Medical Physics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. Electronic address: valeria.faccenda@irccs-sangerardo.it.

Zitieren

APA

Arcangeli, S., Chissotti, C., Ferrario, F., Lucchini, R., Belmonte, M., Purrello, G., Colciago, R. R., De Ponti, E., Faccenda, V., & Panizza, D. (2024). Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.06.030

Vancouver

Arcangeli S, Chissotti C, Ferrario F, Lucchini R, Belmonte M, Purrello G, et al. Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.06.030

BibTeX
@article{Arcangeli2024,
  author = {Arcangeli, Stefano and Chissotti, Chiara and Ferrario, Federica and Lucchini, Raffaella and Belmonte, Maria and Purrello, Giorgio and Colciago, Riccardo Ray and De Ponti, Elena and Faccenda, Valeria and Panizza, Denis},
  title = {Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2024.06.030}
}
Kostenlos starten →